Columnist Caroline Gainer is no longer haunted by a weight gain that was crucial in helping her adapt to her COPD and to her ...

While COPD imposes some limitations, columnist Caroline Gainer has learned that choosing to rest can be a radical act of self ...

November marks COPD Awareness Month, and advocates this year will focus on action, and education about chronic obstructive ...

Each day that I continue to take my antidepressant, I see more and more of the world I used to enjoy before chronic obstructive pulmonary disease (COPD) caused the walls to cave in on me. Though I ...

A Phase 3 clinical trial testing AstraZeneca’s injection therapy benralizumab as a potential treatment for chronic obstructive pulmonary disease (COPD) has failed to meet its main goal of showing the ...

Those of us living with chronic obstructive pulmonary disease (COPD) have learned to pay close attention to subtle changes in our bodies to avoid or quickly address respiratory infections, which can ...

Note: This column describes the author’s own experiences with guaifenesin. Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. We always ...

I have a few tips, tricks, and gadgets that help me live a good life with my chronic obstructive pulmonary disease (COPD). They come during my morning and evening routines, which help us do what’s ...

Digital inhalers that measure and record inhalation data and that can remotely monitor patients may help predict impending chronic obstructive pulmonary disease (COPD) exacerbations, that is, episodes ...

Using e-cigarettes, often called vaping, significantly increases the risk of chronic obstructive pulmonary disease (COPD), a U.S. study suggests. People who used e-cigarettes, which are ...

The U.S. Food and Drug Administration (FDA) has approved Abrysvo, a vaccine that protects against lung infections caused by the respiratory syncytial virus — commonly known as RSV — for adults as ...

The U.S. Food and Drug Administration has cleared the start of clinical trial testing of KT-621, Kymera Therapeutics’ oral therapy for chronic obstructive pulmonary disease (COPD) and other diseases ...